Zoetis Inc.
Zoetis Inc. (ZTS) is a global leader in animal health, developing, manufacturing and commercialising medicines, vaccines and diagnostics for livestock and companion animals. With a market capitalisation of about $64.7bn, the company benefits from steady, recurring demand driven by pet ownership trends, livestock productivity needs and veterinary services growth across developed and emerging markets. Zoetis' strength lies in a diversified product portfolio, a broad geographic footprint and ongoing investment in R&D and targeted acquisitions to expand its pipeline. Investors should note potential advantages — predictable cash flows, margin resilience and dividend capacity — alongside risks such as regulatory scrutiny, pricing pressures, disease outbreaks and currency exposure. Zoetis may suit investors seeking exposure to defensive growth within healthcare, but it is important to assess valuation, portfolio fit and risk tolerance. This information is educational only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future returns.
Why It's Moving
Zoetis Eyes Recovery With Strong 2026 Guidance and Pipeline Catalysts Ahead
- Q4 adjusted EPS of $1.48 beat estimates by $0.08 with revenue of $2.39 billion surpassing consensus, prompting the stock to briefly gain 4.4% in premarket before settling near $146, still 29% below its 52-week high
- 2026 adjusted EPS guidance of $7.00–$7.10 significantly exceeded Wall Street's $6.80 expectation, with analysts noting the raise should alleviate near-term growth concerns despite recent competitive headwinds in dermatology and parasiticides
- Pipeline catalysts including Lenivia's U.S. approval expected in 2027 and international rollout of long-acting osteoarthritis pain products position the company for continued earnings expansion, with the median analyst price target of $156.44 implying roughly 21% upside and some models pricing the stock toward $180
Zoetis Eyes Recovery With Strong 2026 Guidance and Pipeline Catalysts Ahead
- Q4 adjusted EPS of $1.48 beat estimates by $0.08 with revenue of $2.39 billion surpassing consensus, prompting the stock to briefly gain 4.4% in premarket before settling near $146, still 29% below its 52-week high
- 2026 adjusted EPS guidance of $7.00–$7.10 significantly exceeded Wall Street's $6.80 expectation, with analysts noting the raise should alleviate near-term growth concerns despite recent competitive headwinds in dermatology and parasiticides
- Pipeline catalysts including Lenivia's U.S. approval expected in 2027 and international rollout of long-acting osteoarthritis pain products position the company for continued earnings expansion, with the median analyst price target of $156.44 implying roughly 21% upside and some models pricing the stock toward $180
When is the next earnings date for Zoetis Inc. (ZTS)?
Zoetis (ZTS) is scheduled to report Q1 2026 earnings on April 29, 2026, based on the company's historical earnings release pattern. The earnings call will follow the release, providing management commentary on financial results and forward guidance. This report will cover the first quarter of fiscal 2026 and represents the next scheduled quarterly disclosure for investors.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zoetis' stock, which has significant potential to increase in value.
Financial Health
Zoetis is performing well with strong profits, cash flow, and revenue, reflecting healthy demand for its products.
Dividend
Zoetis Inc. offers a below average dividend yield of 1.49%, indicating limited income potential from dividends. If you invested $1000 you would be paid $14.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ZTS
Next-Gen Proteins
Looking to invest in the future of food? This carefully selected group of stocks represents companies solving our global protein challenges. From plant-based alternatives to agricultural innovation, these stocks have been thoughtfully chosen by our analysts for their potential in this growing market.
Published: June 17, 2025
Explore BasketPets Are Family
The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady demand drivers
Rising pet ownership and livestock productivity needs can support predictable revenue, though sales can vary with animal health trends and outbreaks.
Global footprint
A wide geographic reach exposes Zoetis to growth in emerging markets, but also brings currency and regulatory risk across regions.
R&D and pipeline
Ongoing investment in R&D and selective acquisitions fuels future products, yet new launches carry execution and approval risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
